Latest Breaking News On - Eva kalias - Page 3 : comparemela.com

Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomSwitzerland generalUnited statesDario eklundEva kaliasSilvia hornkampEuropean commissionGerman duchenne foundationLife science allianceEuropean unionSanthera pharmaceuticals holdingAmerica to catalyst pharmaceuticalsHead investor relations communicationsDrug administrationRegulatory agencyEuropean medicines agency

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalUnited kingdomEva kaliasShabir hashamLife science allianceEuropean unionRegulatory agencyHead investor relations communicationsSanthera pharmaceuticals holdingAmerica to catalyst pharmaceuticalsDuchenne research fundSanthera pharmaceuticalsEuropean medicines agencyEnergyx ray absorptiometryDrug administration

Santhera Receives Approval for AGAMREE® (Vamorolone) as a

Approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of AGAMREE® in the United Kingdom follows marketing authorization for this.

United statesUnited kingdomSwitzerland generalShabir hashamEva kaliasEuropean medicines agencyAmerica to catalyst pharmaceuticalsEuropean unionLife science allianceHead investor relations communicationsRegulatory agencySanthera pharmaceuticals holdingSanthera pharmaceuticalsDuchenne research fundEnergyx ray absorptiometryEuropean commission

Santhera s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

European Commission (EC) grants marketing authorization for AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE® is the only approved medication in the European Union (EU) for treating DMD, and the first DMD treatment approved in both the U.S. and EUFirst commercial launch of AGAMREE®, in Germany, expected in Q1-2024 EMA acknowledges safety benefits of AGAMREE® with regards to preserving bone health and maintaining growth compared to standard

United kingdomSwitzerland generalUnited statesElizabeth vroomDario eklundEva kaliasEnergyx ray absorptiometryCommittee for medicinal products human useEuropean unionSanthera pharmaceuticalsWorld duchenne organizationHead investor relations communicationsDrug administrationEuropean medicines agencyCatalyst pharmaceuticalsLife science alliance

Santhera Pharmaceuticals Holding AG: Santhera s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG: Santhera s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited statesUnited kingdomElizabeth vroomEva kaliasDario eklundStefan klotterWorld duchenne organizationCatalyst pharmaceuticalsDrug administrationEuropean unionCommittee for medicinal products human useEnergyx ray absorptiometryEuropean medicines agencySanthera pharmaceuticalsEuropean commission